PLIAGLIS (Lidocaine; Tetracaine) Patent Expiration, LOE Window & CMS Spending

PLIAGLIS (Lidocaine; Tetracaine) by Crescita Therapeutics: FDA Orange Book core substance LOE 2031-01-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCrescita Therapeutics
FDA Application & PathwayN021717 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-01-14
Last Listed Patent or Exclusivity Date2031-01-14
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel